[Economic significance of heart failure. An overview of costs and economics of therapy].
The economic burden of congestive heart failure is significant. Approximately 1 to 2% of total health care expenditure is attributed to the diagnosis, treatment and prevention of congestive heart failure. A great share of this expenditure is related to the costs of long-term complications and productivity losses. In order to manage these costs, providers and policymakers increasingly have to focus on economically attractive interventions. Pharmacoeconomic analyses aid the systematic selection of cost-effective drug therapy in congestive heart failure in an era of increasing cost-containment.
Szucs
T D
TD
Abteilung Medizinische Okonomie, Universitätsspital Zürich. thomas.szucs@vdi.usz.ch
Sokolovic
E
E
D000319:Adrenergic beta-Antagonists / Q000191:economics / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D017850:Economics, Pharmaceutical; D005260:Female; D005102:Health Expenditures; D006333:Heart Failure / Q000191:economics* / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors